Log In
Print
BCIQ
Print
Print this Print this
 

inotuzumab ozogamicin (CMC-544, PF-5208773)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionAntibody-drug conjugate (ADC) consisting of a humanized mAb against CD22 linked to the calicheamicin cytotoxin
Molecular Target CD22
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase III
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphocytic leukemia (ALL) in elderly patients; Treat B cell acute lymphoblastic leukemia (ALL); Treat relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL)
Regulatory Designation U.S. - Orphan Drug (Treat acute lymphocytic leukemia (ALL) in elderly patients);
EU - Orphan Drug (Treat acute lymphocytic leukemia (ALL) in elderly patients);
Switzerland - Orphan Drug (Treat B cell acute lymphoblastic leukemia (ALL))
Partner UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today